Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek; Emily K. Dolezal; Michael T. Tees; Sean M. Devlin; Karen Stein; Alejandro Romero; Stephen D. Nimer

doi:10.1016/j.leukres.2012.04.025

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek, Emily K. Dolezal, Michael T. Tees, Sean M. Devlin, Karen Stein, Alejandro Romero, Stephen D. Nimer

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

Original language	English (US)
Pages (from-to)	1093-1097
Number of pages	5
Journal	Leukemia Research
Volume	36
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2012.04.025
State	Published - Sep 2012
Externally published	Yes

Keywords

5-Azacytidine
Decitabine
Leukemia
Therapy-related cancer

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2012.04.025

Cite this

@article{35543150afb44488b91af3d6d99a618c,

title = "Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes",

abstract = "We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.",

keywords = "5-Azacytidine, Decitabine, Leukemia, Therapy-related cancer",

author = "Klimek, {Virginia M.} and Dolezal, {Emily K.} and Tees, {Michael T.} and Devlin, {Sean M.} and Karen Stein and Alejandro Romero and Nimer, {Stephen D.}",

note = "Funding Information: Support for this study was provided by the Leukemia and Lymphoma Society Specialized Center of Research grant for the study of Myeloid Malignancies (S.D.N., V.M.K.) and the William and Marion Shulevitz Fund (V.M.K.). ",

year = "2012",

month = sep,

doi = "10.1016/j.leukres.2012.04.025",

language = "English (US)",

volume = "36",

pages = "1093--1097",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

AU - Klimek, Virginia M.

AU - Dolezal, Emily K.

AU - Tees, Michael T.

AU - Devlin, Sean M.

AU - Stein, Karen

AU - Romero, Alejandro

AU - Nimer, Stephen D.

N1 - Funding Information: Support for this study was provided by the Leukemia and Lymphoma Society Specialized Center of Research grant for the study of Myeloid Malignancies (S.D.N., V.M.K.) and the William and Marion Shulevitz Fund (V.M.K.).

PY - 2012/9

Y1 - 2012/9

N2 - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

AB - We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

KW - 5-Azacytidine

KW - Decitabine

KW - Leukemia

KW - Therapy-related cancer

UR - http://www.scopus.com/inward/record.url?scp=84864008372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864008372&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.025

DO - 10.1016/j.leukres.2012.04.025

M3 - Article

C2 - 22608310

AN - SCOPUS:84864008372

VL - 36

SP - 1093

EP - 1097

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this